Matching articles for "NHL"
Issue 1335 · April 5, 2010
Plerixafor (Mozobil)

The FDA has approved plerixafor ( Mozobil – Genzyme), a CXCR4 chemokine receptor antagonist, for use in combination with granulocyte-colony stimulating factor (G-CSF; Neupogen ) to mobilize peripheral blood…

Med Lett Drugs Ther. 2010 Apr 5; 52(1335):27-8
The FDA has approved plerixafor ( Mozobil – Genzyme), a CXCR4 chemokine receptor antagonist, for use in combination with granulocyte-colony stimulating factor (G-CSF; Neupogen ) to mobilize peripheral blood stem cells in adults with multiple myeloma or non-Hodgkin’s lymphoma before high-dose chemotherapy with autologous stem cell rescue.
Issue 1300 · December 1, 2008 Free
Correction: Bendamustine (Treanda) for CLL and NHL

(Med Lett Drugs Ther 2008; 50:91) In the Clinical Studies section, the complete response rate with chlorambucil for CLL was 2% (not 24%).

Med Lett Drugs Ther. 2008 Dec 1; 50(1300):96
(Med Lett Drugs Ther 2008; 50:91) In the Clinical Studies section, the complete response rate with chlorambucil for CLL was 2% (not 24%).
Issue 1299 · November 17, 2008
Bendamustine (Treanda) for CLL and NHL

Bendamustine HCl ( Treanda - Cephalon), an unusual DNA-alkylating agent that has been used in Europe for many years to treat lymphoma, has now been approved by the FDA for treatment of chronic lymphocytic…

Med Lett Drugs Ther. 2008 Nov 17; 50(1299):91-2
Bendamustine HCl ( Treanda - Cephalon), an unusual DNA-alkylating agent that has been used in Europe for many years to treat lymphoma, has now been approved by the FDA for treatment of chronic lymphocytic leukemia (CLL) and non-Hodgkin's lymphoma (NHL).
Issue 1168 · October 27, 2003
Iodine-131 Tositumomab (Bexxar) for Treatment of Lymphoma

Bexxar , a combination of the monoclonal antibody tositumomab and radiolabeled Iodine-131 tositumomab (Corixa Corp/GlaxoSmithKline) has been approved by the FDA for a single treatment of relapsed follicular…

Med Lett Drugs Ther. 2003 Oct 27; 45(1168):86-7
Bexxar , a combination of the monoclonal antibody tositumomab and radiolabeled Iodine-131 tositumomab (Corixa Corp/GlaxoSmithKline) has been approved by the FDA for a single treatment of relapsed follicular non-Hodgkin's lymphoma (NHL) in patients who are refractory to rituximab ( Rituxan - Medical Letter 1998; 40:65). It is the second radioimmunoconjugate to be approved for refractory NHL; yttrium-90 linked to ibritumomab tiuxetan (Zevalin) was approved in 2002. Tositumomab, like ibritumomab, is a monoclonal antibody of mouse origin that binds to the CD20 antigen present on the surface of >90% of malignant B cells.
Issue 1144 · November 25, 2002
Ibritumomab Tiuxetan (Zevalin) for Non-Hodgkin's Lymphoma

Yttrium-90 ibritumomab tiuxetan ( Zevalin -IDEC) was approved by the FDA for treatment of patients with relapsed or refractory low-grade follicular or transformed B-cell non-Hodgkin's lymphoma (NHL), including…

Med Lett Drugs Ther. 2002 Nov 25; 44(1144):101-2
Yttrium-90 ibritumomab tiuxetan ( Zevalin -IDEC) was approved by the FDA for treatment of patients with relapsed or refractory low-grade follicular or transformed B-cell non-Hodgkin's lymphoma (NHL), including patients with follicular lymphoma refractory to rituximab ( Rituxan -Medical Letter 1998; 40:65). Zevalin is the first radioimmunoconjugate to be approved for treatment of cancer.